



| 货号 | YP115036 |
|---|---|
| 品牌 | abinScience |
| 描述 |
Naxitamab (YP115036) is a research-grade recombinant antibody targeting Ganglioside GD2. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 种属反应性 | General |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Chimeric |
| 同种型 | IgG1, kappa |
| 表达系统 | Mammalian cells |
| 克隆类型 | Monoclonal |
| 靶标 | Ganglioside GD2 |
| 内毒素水平 | < 10 EU/mg |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 别名 | Hu3F8, Naxitamab-gqgk, CAS: 1879925-92-4 |
| 背景 | Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. • Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246 • GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214 • Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230 • Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234 • Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234 • Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849 • RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168 • Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas., PMID:29662203 • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SEC-HPLC detection for Research Grade Naxitamab.

SDS-PAGE for Research Grade Naxitamab.





24小时产品查询

扫一扫关注我们

专属渠道经理